| 产品描述: | MF-766 is a highly potent, selective and orally active EP4 antagonist with a Ki of 0.23 nM. MF-766 behaves as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. MF-766 can be used for cancer and inflammation diseases research |
| 靶点: |
EP4:0.23 nM (Ki);ProstaglandinReceptor |
| 体外研究: |
MF-766 (0.01-10 μM;预处理 1 小时,然后用 50 ng/mL IL-2 刺激;有和没有 0.33 μM PGE2;18 小时) 逆转人 NK 细胞中 PGE2 抑制的 IFN-γ 分泌。此外,NK 细胞活力不受 MF-766 的影响 |
| 体内研究: |
MF-766 (口服强饲法;30 mg/kg;每天一次;21 天) 在 CT26 肿瘤模型中表现出 49% 的肿瘤抑制率。但它在 EMT6 和 4T1 肿瘤模型中没有表现出显著差异。 MF-766 (口服灌胃;30 mg/kg 联合抗 PD-1 mDX400;每天一次;21 天;q4dx8) 在不同的临床前模型中显示出有效的抗肿瘤活性。CT26 肿瘤、EMT6 肿瘤和 4T1 肿瘤模型中肿瘤抑制率的百分比分别为 89%、66% 和 40%。 Animal Model: Female C57BL/6 J strain mice injected subcutaneously with CT26, EMT6, or 4T1 cells Dosage: 30 mg/kg combination with anti-PD-1 mDX400 Administration: Oral gavage; 10 mg/kg or 30 mg/kg combination with anti-PD-1 mDX400; once daily; 21 days; q4dx8 Result: Improved anti-tumor activity in the setting of PD-1 blockade in multiple syngeneic models. |
| 参考文献: |
1. John Colucci, et al. Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3760-3. 2. Yun Wang, et al. Combination of EP 4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. Oncoimmunology. 2021 Mar 18;10(1):1896643. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.09 ml |
10.45 ml |
20.9 ml |
| 5 mM |
0.418 ml |
2.09 ml |
4.18 ml |
| 10 mM |
0.209 ml |
1.045 ml |
2.09 ml |
| 50 mM |
0.042 ml |
0.209 ml |
0.418 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |